Background {#Sec1}
==========

Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease of childhood, defined as progressive deterioration of muscle tissue and resultant weakness, which affects 1 in 3600--6000 male live births \[[@CR1], [@CR2]\]. It is an X-linked recessive disease caused by mutations in the *DMD* gene. This gene spans a genomic range of 2.2 Mb and contains 79 exons and 8 promoters. *DMD* gene encodes a protein of dystrophin--glycoprotein complex, which bridges the inner cytoskeleton and the extracellular matrix. The remarkably reduced levels or absence of dystrophin protein is caused by mutations of *DMD* gene, resulting in chronic muscle damage and eventually loss of muscle function in patients with DMD \[[@CR3]\].

Many mutations have been described since the discovery of *DMD* gene in 1986 \[[@CR4]\]. The mutational studies have indicated that deletions or duplication of exons accounts for approximately 65% of all mutations \[[@CR5], [@CR6]\]. Multiplex ligation-dependent probed amplification (MLPA) has been developed to detect the large fragments of deletions or duplications spanning one or more exons \[[@CR7]\]. The remaining anomalies are thought to be caused by point mutations, mainly nonsense, frameshift mutations, and small deletion and insertion mutations \[[@CR8], [@CR9]\]. The traditional Sanger sequencing of 79 exons of *DMD* gene is costly and time-consuming, making it no appropriate for the purpose of detecting point mutations in *DMD* gene. The target next-generation sequencing technology (NGS), known as deep sequencing, has been widely applied to detect all types of mutations in the *DMD* gene \[[@CR10], [@CR11]\].

In the present study, clinical experience of stepwise diagnosis of 62 families with a history of DMD coming to our center in the last 4 years were reported. Firstly, the proband in the families was analyzed using MLPA and NGS. Secondly, the mother carrier status in the families was investigated. Finally, the prenatal diagnosis of fetuses was offered to the pregnant mother.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

The study was performed at the Department of Prenatal Diagnosis in Women's Hospital of Nanjing Medical University between 2015 and 2018. A total of 155 individuals coming from 62 families with a history of DMD were included in the present study. The female members of the 62 families were in pregnancy or preparing for pregnancy, and 34 pregnant women were referred for the prenatal diagnosis of DMD. The workflow reflected the procedures of the patient management in our study (Fig. [1](#Fig1){ref-type="fig"}). This study was approved by the ethics committee of Women's Hospital of Nanjing Medical University. Written informed consent was obtained from the patients or their guardians. Fig. 1Flowchart for prenatal diagnosis of DMD

Genomic DNA samples {#Sec4}
-------------------

A total of 2 mL of peripheral blood was collected from patients to obtain genomic DNA. For the pregnant women, 10 mL of amniotic fluid was collected at 18--24 weeks gestation for prenatal diagnosis. Genomic DNA was extracted according to the protocol of the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany).

Multiplex ligation-dependent probe amplification {#Sec5}
------------------------------------------------

The SALSA MLPA P034 and P035 kits (MRC-Holland, Amsterdam, Netherlands) were used to detect the deletion or duplication of *DMD* gene. After denaturation, hybridization, ligation, and amplification, the products were examined using an ABI 3500Dx genetic analyzer (Thermo Fisher, USA). The initial data were analyzed using the Coffalyser software V8.0 (<http://www.mlpa.com/coffalyser>). The 30% increase or decrease in the relative peak area of the probe revealed the duplication or deletion of the exons of *DMD* gene, respectively.

Next-generation sequencing (NGS) {#Sec6}
--------------------------------

NGS was used for the point mutation analysis of *DMD* gene in the patients and their family, which was performed using Ion AmpliSeq™ panel of 382 inherited disease-associated genes on an Ion Torrent Personal Genome Machine platform (Life Technologies, MA, USA). Briefly, the Ion AmpliSeq Inherited Disease Panel (Life Technologies, MA, USA) employs over 10,000 primer pairs in just 3 tubes to amplify the exons of 328 genes. After amplification, the library of the target exons was prepared using the Ion Ampliseq Library Kit 2.0 (Life Technologies, MA, USA). The emulsion polymerase chain reaction was carried out using the Ion OneTouch System and Ion PGM Hi-Q View OT2 Kit (Life Technologies, MA, USA)). Then, the template-positive Ion Sphere particles were enriched using the Dynabeads MyOne Streptavidin C1 Beads and washed using the Ion OneTouch Wash Solution (Life Technologies, MA, USA)). Sequencing was performed with the PGM system using the Ion PGM Hi-Q View Sequencing Kit and Ion 318 Chip V2 (Life Technologies, MA, USA) according to the manufacturer's protocol. Two samples were tested per run. All the sequencing data were analyzed with the standard Ion Torrent Suite software 4.2. The human genome GRCh37/hg19 was used as a reference, and all the detected variants were filtered against dbSNP142. The sequencing results were viewed using the Integrated Genomic Viewer. In addition, Sanger sequencing was used to confirm the most likely disease-causing variants.

Results {#Sec7}
=======

Exons deletion or duplication of DMD gene was detected by MLPA {#Sec8}
--------------------------------------------------------------

Among the 62 families with a history of DMD, exon deletion or duplication was detected in 32 families (32/62, 51.6%) using MLPA (Table [1](#Tab1){ref-type="table"}). The rearrangements contained 31 large deletions and 1 large duplication, accounting for 50% (31/62) and 1.6% (1/62) of families involved in this study, respectively. Single-exon deletions (5/62, 8.1%), which have been verified by RT-PCR, were the most common types of deletions, followed by six-exon deletions (3/62, 4.8%). Exon 49 and 50 were the most frequently deleted exons in 32 families with exon rearrangements. Table 1The mutation spectrum of DMD patients in 52 familiesFamily numberExon IDBase changeEffectMutation typeCarrier status of motherStatus1Exon66c.9568C \> Tp.Arg3190\*NonsenseYesReported2Exon47c.6804_6807delACAAp.Lys2268Asnfs\*2Small deletionsYesReported3Intron65c.9564-427 T \> GSplicingNoReported4Exon22c.2929C \> Tp.Gln977\*NonsenseYesReported5Exon7c.583C \> Tp.Arg195\*NonsenseYesReported6Exon41c.5899C \> Tp.Arg1967\*NonsenseYesReported7Exon40c.5591_5592insTp.Leu1864phefs\*24Small insertionsYesReported8Exon40c.5697delAp.Lys1899AsnfsSmall deletionsYesReported9Exon16c.1978_1979delAAp.K660Efs\*59Small deletionsYesReported10Exon14c.1652G \> Ap.W551\*NonsenseYesReported11Exon14c.1615C \> Tp.Arg539\*NonsenseYesReported12Intron45c.6615-2A \> GSplicingYesReported13Exon6c.412A \> Tp.Lys138\*NonsenseYesNovel14Exon56c.8299G \> Tp.E2767\*NonsenseYesReported15Exon62c.9204_9207delCAAAp.Asn3068LysfsSmall deletionsYesReported16Exon23c.2962delTp.Ser988Leufs\*16Small deletionsYesNovel17Exon75c.10705A \> Tp.Lys3569\*NonsenseYesNovel18Exon47c.6850dupAp.Ser2284Lysfs\*7Small insertionsYesNovel19Exon36c.5139dupAp.E1714Rfs\*5Small insertionsYesNovel20Exon43c.6201_6203delGCCinsCCCAp.Val2069Cysfs\*14Small deletions and insertionsYesNovel21Exon8--17DupYesReported22Exon12--29DelYesReported23Exon48--50DelYesReported24Exon47--50DelNoReported25Exon49--52DelYesReported26Exon49--50DelYesReported27Exon46--52DelYesReported28Exon45--47DelYesReported29Exon46--48DelYesReported30Exon1--44DelYesReported31Exon46--52DelYesReported32Exon1--60DelYesReported33Exon47--50DelYesReported34Exon49--52DelYesReported35Exon45DelYesReported36Exon51--54DelNoReported37Exon51--54DelNoReported38Exon10--11DelYesReported39Exon18--41DelYesReported40Exon17DelYesReported41Exon51--55DelNoReported42Exon45--50DelYesReported43Exon48--50DelYesReported44Exon50DelNoReported45Exon45--50DelNoReported46Exon45DelNoReported47Exon50DelYesReported48Exon45--52DelNoReported49Exon31--44DelYesReported50Exon49--51DelYesReported51Exon43--44DelYesReported52Exon45--50DelYesReported

Point mutations of DMD gene were identified by NGS {#Sec9}
--------------------------------------------------

The remaining 30 families with negative MLPA results were further investigated using NGS. Point mutations were identified in 20 families (20/62, 32.3%), including 9 (9/62, 14.5%) nonsense mutations, 5 (5/62, 8.1%) small deletion mutations, 3 (3/62, 4.8%) small insertion mutations, 2 (2/62, 3.2%) splicing mutations, and 1 (1/62, 1.6%) small deletion and insertion mutation (Table [1](#Tab1){ref-type="table"}). Of all point mutations, six novel mutations were identified in six unrelated families (Fig. [2](#Fig2){ref-type="fig"}). All the six novel mutations led to premature termination codons, which was expected to produce truncated dystrophin protein (Table [2](#Tab2){ref-type="table"}). In addition, 10 families had a negative result from findings of MLPA and NGS. Therefore, clinical reevaluation or tests using other molecular methods would be required to achieve a genetic diagnosis for the probands in those 10 families. Fig. 2Novel mutations were detected using NGS and verified by Sanger sequecing. NGS reads were shown on the Integrative Genomics Viewer. **a** showed the novel mutation of c.412A \> T; **b** showed the novel mutation of c.2962delT; **c** showed the novel mutation of c.5139 dupA; **d** showed the novel mutation of c.6201_6203 delGCCinsCCCA; **e** showed the novel mutation of c.6805dupA; **f** showed the novel mutation of 10705A \> T Table 2The novel mutations diagnosed by NGSFamiliy numberAge of proband (years old)CK value (U/L)ExonIDBase changeEffectMutation typeCarrier status of mother1388616Exon6c.412A \> Tp.Lys138\*NonsenseYes16312,817Exon23c.2962delTp.Ser988Leufs\*16Small deletionsYes1719880Exon75c.10705A \> Tp.Lys3569\*NonsenseYes181019,964Exon47c.6850dupAp.Ser2284Lysfs\*7Small insertionsYes19114880Exon36c.5139dupAp.E1714Rfs\*5Small insertionsYes2056179Exon43c.6201_6203delGCCinsCCCAp.Val2069Cysfs\*14Small deletions and insertionsYes*CK* Creatine kinase

Mother carrier status and prenatal diagnosis were investigated by MLPA and sanger sequencing {#Sec10}
--------------------------------------------------------------------------------------------

The mother carrier status was analyzed using MLPA or NGS according to the mutation types of the proband. The results indicated that 45 mothers (45/52, 86.5%) were the carriers, whereas 7 mothers (7/52, 13.5%) did not carry the mutation (Table [1](#Tab1){ref-type="table"}). In the 32 families with exon deletions or duplications, 6 mothers did not have the mutations identified from the proband of the family. Whereas, in the 20 families with point mutations, only 1 mother did not carry the mutation.

According to the results of proband and their mothers, 34 fetuses were tested when the mothers had another pregnancy. Due to the possible germline mosaicism, prenatal diagnosis was suggested to the mothers whether they carried pathogenic mutations or not. The results of prenatal diagnosis showed that eight male fetuses carried the same mutations as the proband, three female fetuses had a carrier status, and the remaining fetuses carried no pathogenic mutation (Table [3](#Tab3){ref-type="table"}). According to the family information and the mutation results, we summarized the pedigree patterns of 62 DMD families (Fig. [3](#Fig3){ref-type="fig"}). Table 3Prenatal diagnosis of 34 fetuses in high-risk families with DMD family historyFamily numberProbandCarrier status of motherFetusPregnancy outcome1c.9568C \> TYes----2c.6804_6807delACAAYes----2c.6804_6807delACAAYes+Termination3c.9564-427 T \> GNo----10c.1652G \> AYes+Termination12c.6615-2A \> GYes----13c.412A \> TYes----14c.8299G \> TYes----15c.9204_9207delCAAAYes+Termination21Exon8--17Yes----23Exon48--50Yes----24Exon47--50No----25Exon49--52Yes----26Exon49--50Yes+Termination27Exon46--52Yes+Termination28Exon45--47Yes+Termination31Exon46--52YesCarrier--33Exon47--50Yes----34Exon49--52Yes----36Exon51--54No----37Exon51--54No----39Exon18--41Yes----40Exon17Yes----41Exon51--55No----42Exon45--50Yes----44Exon50No----45Exon45--50No----46Exon45No----47Exon50YesCarrier--48Exon45--52No----49Exon31--44Yes+Termination50Exon49--51Yes+Termination51Exon43--44YesCarrier--52Exon45--50Yes---- Fig. 3The pedigree patterns of DMD families. ■ and the arrowhead mean the proband of the family. ☉means the carrier in the family. F. means the fetus

Discussion {#Sec11}
==========

Many patients with a family history of genetic diseases have visited our center. If a proband was confirmed in the family, the members of the family would be worried about their next generation and strongly wished to determine the genetic causes to avoid having the fetus with the same disease. In the present study, data from patients with DMD were retrieved and analyzed. A total of 155 individuals deriving from 62 families with a history of DMD were included in the study. In all, 32 different large rearrangements and 20 point mutations including 6 novel mutations, were identified in 62 probands of the families using MLPA and NGS.

MLPA has been used to detect the large rearrangements of *DMD* gene since its discovery by Schouten in 2002 \[[@CR12]\]. To date, it was reported that approximately 65% patients showed exon deletions or duplications in the *DMD* gene \[[@CR5], [@CR6]\]. The results of the present study demonstrated that 51.6% of the probands had large rearrangements, which was slightly lower than that in the similar studies (70.5% \[[@CR7]\], 71% \[[@CR13]\], 78.7% \[[@CR14]\]). The remaining mutations were detected using NGS, and point mutations accounted for 32.3% of the molecular pathology in *DMD* gene in our study, which was slightly higher than that in other studies (30%) \[[@CR8]\] (Table [1](#Tab1){ref-type="table"}). It was believed that these differences could be due to the sample size and sample source. In China, MLPA has been widely used in many hospitals and laboratories, while NGS is applied in only a few centers because of its high requirement for laboratory conditions and complex data analysis. In our center, the *DMD* gene could be tested using not only MLPA but also NGS. Therefore, many patients visited the center for detecting point mutations when their MLPA results were negative in other laboratories. As a result, the present study showed a lower rate of rearrangement and a higher rate of point mutations, compared with the findings of the other studies of DMD.

Further, many novel point mutations could be found in the *DMD* gene using NGS. Wang et al. reported that about one third of the mutations could be firstly identified in patients with DMD \[[@CR8]\]. This study reported six novel mutations in patients with DMD (Table [2](#Tab2){ref-type="table"}). All the six novel mutations (c.412A \> T, c.2962delT, c.10705A \> T, c.6850dupA, c.5139 dupA and c.6201_6203delGCCinsCCCA) led to a premature stop codon, resulting in the production of a shortened dystrophin protein, which could harm the normal function of dystrophin.

To date, no effective therapies are available for patients with DMD. Therefore, families with a history of DMD showed anxiety and strongly requested prenatal diagnosis to avoid having another child with DMD. The proband's mother and other related female family members were suggested to accept genetic counseling and carrier testing. In the present cohort, the results demonstrated that 45 (45/52, 86.5%) mothers were carriers. If the mother was not a carrier, her son with DMD mostly had a de novo mutation. However, germline mosaicism in DMD should not be ignored as described as early as in the 1980s \[[@CR15], [@CR16]\]. Wang et al. reported 3 cases of germline mosaicism in 50 mothers with no pathogenic mutations, suggesting that mosaicism should be considered in the genetic counseling. In our center, prenatal diagnosis was recommended to pregnant women whether they carried the disease-causing mutations or not. In the present study, a total of 34 pregnant women accepted the prenatal diagnosis. The results demonstrated that eight male fetuses were affected, three female fetuses were carriers, and the remaining were normal for the identified mutations in the families respectively (Table [3](#Tab3){ref-type="table"}).

In this study, 10 families did not have positive mutations according to the complete analysis of the exons of the *DMD* gene. Besides *DMD* gene, the exons of 381 inherited disease-associated genes in the disease panel were negative for pathogenic mutations in our study. These genes are associated with over 700 inherited diseases including some other neuromuscular diseases. The detailed diseases are shown in the web: [lifetechnologies.com](http://lifetechnologies.com)/ ampliseqready. Therefore, the clinical diagnosis should be firstly revised in further research. If the manifestations and muscle biopsies were consistent with DMD, the introns of the *DMD* gene should be comprehensively investigated. If the results for introns of DMD gene were still negative, the other muscle disease panels or whole-genome sequencing could be used to analyze the pathogenic mutations.

Conclusions {#Sec12}
===========

DMD causes great harm to many patients and their families due to the lack of effective therapies. Accurate genetic and prenatal diagnoses are urgently needed for the families with a history of DMD to avoid having children with DMD. In this retrospective study, MLPA and NGS were combined for the genetic analysis and prenatal diagnosis of 62 Chinese families with DMD proband. Meanwhile, six novel pathogenic point mutations in the *DMD* gene were reported. Generally, when the family members with a history of DMD came to the center, MLPA was first performed for detecting exon deletions or duplications. If the MLPA results were negative, NGS was used to detect the mutations. If positive results were obtained, the carrier testing of the mother was performed. Considering germline mosaicism, the prenatal diagnosis was proposed to all the pregnant women in these families whether they carried the disease-causing mutations or not. If the mutation can not be determined using MLPA and NGS, the clinical information should be evaluated and other methods could be used to uncover the underlying pathogenic mutations (Fig. [1](#Fig1){ref-type="fig"}).
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